Stereotaxis (STXS) Receivables - Other (2010 - 2026)

Stereotaxis' (STXS) quarterly Receivables - Other came in at $4.3 million in Q1 2026, little changed on a QoQ basis from $4.3 million in Q4 2025.

Stereotaxis (STXS) Receivables - Other (2010 - 2026) Analysis & Trends

Stereotaxis (STXS) has 9 years of Receivables - Other data on file, last reported at $4.3 million in Q1 2026.

On a quarterly basis, Receivables - Other changed N/A year-over-year to $4.3 million in Q1 2026; TTM through Mar 2026 was $4.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $4.3 million, changed N/A from the prior year.
Receivables - Other for Q1 2026 stood at $4.3 million, roughly flat from $4.3 million in the prior quarter.
Over the last five years, Receivables - Other for STXS reached as high as $4.3 million in Q4 2025 and fell as low as $4.3 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alcon	32,734,969.19 Bn	32,734,967.53 Bn	1.53 Bn
2	Intuitive Surgical	117.50 Bn	112.41 Bn	1.96 Bn
3	Becton Dickinson	42.93 Bn	42.11 Bn	2.15 Bn
4	Medline	30.82 Bn	36.66 Bn	1.84 Bn
5	Resmed	27.90 Bn	26.23 Bn	890.98 Mn
6	West Pharmaceutical Services	26.76 Bn	26.23 Bn	329.20 Mn
7	Cooper Companies	15.30 Bn	15.16 Bn	735.40 Mn
8	Solventum	13.46 Bn	12.90 Bn	1.10 Bn
9	Align Technology	12.02 Bn	10.96 Bn	736.59 Mn
10	Stereotaxis	136.49 Mn	121.87 Mn	3.79 Mn

Download Data